German Breast Group (GBG)
The German academic group whose GeparX trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer.
Founded 1997 (Gunter von Minckwitz, Sibylle Loibl). GeparSixto (carboplatin raises pCR in TNBC), GeparNuevo (durvalumab), GeparDouze, and the pCR-as-surrogate meta-analyses that shaped neoadjuvant trial design.
- Gepar neoadjuvant trial series
- pCR surrogacy research
Pathologist who established tumour-infiltrating lymphocytes as a biomarker in breast cancer.
Founded the German Breast Group and led KATHERINE, which made T-DM1 standard after residual disease.
Leads the German Breast Group, whose GeparX trials defined neoadjuvant chemotherapy and immunotherapy in breast cancer.
Pages like this
not linked directly; found by shared links- TrialKATHERINE
Shares Gunter von Minckwitz, NSABP Foundation, Pathologic complete response (pCR).
- Key paperKATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment
Shares Gunter von Minckwitz, Sibylle Loibl, Pathologic complete response (pCR).
- Key paperKEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer
Shares Carsten Denkert, Pathologic complete response (pCR), Carboplatin, Triple-negative breast cancer (TNBC).
- InstitutionGerman Hodgkin Study Group
Shares GHSG HD21, Hodgkin lymphoma.
- TrialMATTERHORN
- PersonTakayuki Ueno
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).
- TechnologyPET-adapted (response-adapted) therapy
Shares GHSG HD21, Hodgkin lymphoma.
- InstitutionBreast International Group (BIG)
Shares Austrian Breast & Colorectal Cancer Study Group, Secrecy and intellectual property block collaboration, Triple-negative breast cancer (TNBC).